September 2023 updates to the website

The website has now been updated following September's LSCMMG

The following guidelines have been added/updated:

Gout guideline - updated

Erectile dysfunction guideline - updated

Melatonin Pathway (Children) - added

Lithium shared care guideline - updated

COPD desktop guideline - Update to follow in October

The following medicines have been updated:

Eluxadoline - Treating irritable bowel syndrome with diarrhoea (NICE TA471): removed from website

Rimegepant - Preventing migraine (NICE TA906)

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Brimonidine Tartrate (Mirvaso) 3mg/g Gel - symptomatic treatment of moderate to severe facial erythema of rosacea in adult patients

Ibandronic acid 50 mg Tablets - adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence (unlicensed indication)

Flupentixol (as dihydrochloride) - schizophrenia and other psychoses

Sodium fluoride 1.1%toothpaste (Duraphat) - For use by patients suffering head and neck cancer patients who have had surgery, radiotherapy and/or chemotherapy.

Bempedoic acid with ezetimibe - for treating primary hypercholesterolaemia or mixed dyslipidaemia (RAG review)

Cenobamate - treating focal onset seizures in epilepsy (NICE TA753) (RAG review)